Researchers conducted a subgroup analysis of the SPRINT clinical trial to determine whether intensive blood pressure treatment outcomes were similar in patients with prediabetes vs normal fasting blood glucose levels.
A new point-of-care C peptide test may increase ease and access to testing for patients with type 1 and type 2 diabetes.
Canagliflozin reduced levels of cardiovascular stress biomarkers N-terminal pro-B type natriuretic peptide and high sensitivity troponin I.
False blood glucose elevations, caused by medication interference, are common in critically ill children.
At 3 months, ezetimibe produced greater reductions in LDL cholesterol, whereas colesevelam produced greater reductions in HbA1c levels.
At 12 years of testosterone treatment, HbA1c decreased to 5.5±0.3%.
Flow mediated dilation changes improved in patients who received dapagliflozin.
Sitagliptin improved glucose excursion and lowered triglyceride levels in men with prediabetes who were also overweight.
Interventions seeking to counteract antipsychotic-induced weight gain and cardiometabolic disturbances have had limited success.
Researchers assessed whether neurolysis could alleviate pain associated with diabetic neuropathy.
Please login or register first to view this content.
